Our study indicates that the cross-talk may exist between CXCR2 and EGFR in HCC cells, demonstrated by the finding that the EGF-induced production of CXCL8 was decreased by CXCR2 inhibitor in a dose-dependent pattern. Here, CXCR2 is linked to hepatocellular carcinoma.